Calyxt (CLXT) versus Evogene (EVGN) Head to Head Survey

Evogene (NASDAQ: EVGN) and Calyxt (NASDAQ:CLXT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Profitability

This table compares Evogene and Calyxt’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evogene -462.56% -24.88% -22.64%
Calyxt -5,969.52% -101.69% -76.32%

Earnings and Valuation

This table compares Evogene and Calyxt’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Evogene $6.54 million 15.08 -$19.59 million ($0.83) -4.61
Calyxt $390,000.00 1,302.14 -$12.08 million N/A N/A

Calyxt has higher revenue, but lower earnings than Evogene.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Evogene and Calyxt, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evogene 0 0 0 0 N/A
Calyxt 0 1 3 0 2.75

Calyxt has a consensus target price of $27.75, indicating a potential upside of 51.31%. Given Calyxt’s higher probable upside, analysts clearly believe Calyxt is more favorable than Evogene.

Institutional and Insider Ownership

31.2% of Evogene shares are owned by institutional investors. Comparatively, 12.6% of Calyxt shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Evogene beats Calyxt on 5 of the 9 factors compared between the two stocks.

About Evogene

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). It operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The Company’s Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The Company’s Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.

About Calyxt

Calyxt, Inc. is a food and agriculture company. The Company is focused on delivering healthier specialty food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits, such as herbicide tolerance to farmers. The Company also combines gene-editing technology and technical that enables to edit a plant genome to elicit the desired traits and characteristics. The Company products include Consumer Centric and Farmer Centric products. Consumer Centric product, which includes high oleic soybean, high fiber wheat, high fiber wheat II, reduced gluten wheat, cold storable potato and reduced browning potato. Farmer Centric products, which includes drought tolerant soybean, improved soybean, herbicide tolerant wheat, herbicide tolerant canola, herbicide tolerant alfalfa and herbicide quality alfalfa.The Company has several products under development including high oleic soybeans, powdery mildew resistant wheat and cold storable potato.

What are top analysts saying about Evogene Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Evogene Ltd. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit